Tabei Faraj, Neshandar Asli Isa, Azizmohammadi Zahra, Javadi Hamid, Assadi Majid
Department of Medical Physics and Engineering, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Radiat Prot Dosimetry. 2012 Dec;152(4):323-7. doi: 10.1093/rpd/ncs063. Epub 2012 May 4.
Radioiodine ((131)I iodide) has long been a safe, effective and widely used treatment in the management of differentiated thyroid cancer (DTC). Concerns regarding stochastic radiogenic risks have led to regulatory criteria for the release from medical confinement of patients who receive such radionuclide therapy. Over a 6-y period, the external whole-body dose rates at 1 m from 562 DTC patients were measured with an ionisation chamber calibrated in microsieverts per hour out to 5-d post-administration. Patients were stratified into four administered activity groups: 3.7 GBq (36.8 %), 5.55 GBq (47.3 %), 7.4 GBq (12.8 %) and 9.25 GBq (3 %). Consistent with previously published data, the current study demonstrated that a bi-phasic model accurately described (131)I-iodide kinetics up to at least 5-d post-administration in DTC patients, providing data that would be useful in formulating radiation safety guidelines for staff and other individuals coming into contact with such patients after treatment.
放射性碘（（131）I 碘化物）长期以来一直是分化型甲状腺癌（DTC）治疗中一种安全、有效的广泛应用的治疗方法。对随机辐射风险的担忧导致了对接受此类放射性核素治疗患者解除医学隔离的监管标准。在6年的时间里，使用校准为每小时微希沃特的电离室测量了562例DTC患者给药后5天内距离患者1米处的全身外照射剂量率。患者被分为四个给药活度组：3.7 GBq（36.8%）、5.55 GBq（47.3%）、7.4 GBq（12.8%）和9.25 GBq（3%）。与先前发表的数据一致，当前研究表明，双相模型能够准确描述DTC患者给药后至少5天内（131）I碘化物的动力学，为制定治疗后接触此类患者的工作人员和其他人员的辐射安全指南提供了有用的数据。
